MoonLake Immunotherapeutics
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
MLTX$12.62+9.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in E
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
| Class A Ordinary Shares · Class C Ordinary Shares · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total Shareholders' Equity · Noncontrolling Interests · Total Equity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands except share data) · Shares · Amount · Shares · Amount | ||||||||||
| Balance at January 1, 2025 | 63,077,431 | $6 | 841,269 | $— | $677,415 | $(235,593) | $4,997 | $446,825 | $6,566 | $453,391 |
| Share-based compensation under the Employee Share Participation Plan and the Equity Incentive Plan | — | — | — | — | 2,279 | — | — | 2,279 | 11 | 2,290 |
| Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares | 111,949 | — | (111,949) | — | 841 | — | 10 | 851 | (851) | — |
| Options exercised and converted under the Employee Stock Option Plan, net of stamp duty fee | 93,347 | — | — | — | 129 | — | — | 129 | (9) | 120 |
| Issuance of Restricted Stock Awards under the Equity Incentive Plan | 191,526 | — | — | — | — | — | — | — | — | — |
| Net loss for the three months ended March 31, 2025 | — | — | — | — | — | (39,944) | — | (39,944) | (615) | (40,559) |
| Other comprehensive loss | — | — | — | — | — | — | (2,620) | (2,620) | (41) | (2,661) |
| Balance at March 31, 2025 | 63,474,253 | $6 | 729,320 | $— | $680,664 | $(275,537) | $2,387 | $407,520 | $5,061 | $412,581 |
| Share-based compensation under the Employee Share Participation Plan and the Equity Incentive Plan | — | — | — | — | 3,298 | — | — | 3,298 | 11 | 3,309 |
| Net loss for the three months ended June 30, 2025 | — | — | — | — | — | (55,220) | — | (55,220) | (831) | (56,051) |
| Other comprehensive loss | — | — | — | — | — | — | (1,867) | (1,867) | (28) | (1,895) |
| Balance at June 30, 2025 | 63,474,253 | $6 | 729,320 | $— | $683,962 | $(330,757) | $520 | $353,731 | $4,213 | $357,944 |
| Share-based compensation under the Employee Share Participation Plan and the Equity Incentive Plan | — | — | — | — | 3,698 | — | — | 3,698 | 10 | 3,708 |
| Net loss for the three months ended September 30, 2025 | — | — | — | — | — | (69,729) | — | (69,729) | (965) | (70,694) |
| Other comprehensive loss | — | — | — | — | — | — | (244) | (244) | (3) | (247) |
| Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares | 203,142 | — | (203,142) | — | 968 | — | 2 | 970 | (970) | — |
| Options exercised under the Equity Incentive Plan | 27,149 | — | — | — | 480 | — | — | 480 | — | 480 |
| Balance at September 30, 2025 | 63,704,544 | $6 | 526,178 | $— | $689,108 | $(400,486) | $278 | $288,906 | $2,285 | $291,191 |
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
| Class A Ordinary Shares · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total Shareholders' Equity | ||||||
|---|---|---|---|---|---|---|
| (in thousands except share data) · Shares · Amount | ||||||
| Balance at January 1, 2026 | 71,373,579 | $7 | $766,781 | $(462,911) | $604 | $304,481 |
| Share-based compensation under the Employee Share Participation Plan and the Equity Incentive Plan | — | — | 13,355 | — | — | 13,355 |
| Issuance of Restricted Stock Awards under the Equity Incentive Plan | 354,296 | — | — | — | — | — |
| Options exercised under the Equity Incentive Plan | 69,632 | — | 170 | — | — | 170 |
| Issuance of Class A Ordinary Shares under the Sales Agreement, net of transaction costs | 336,559 | — | 6,007 | — | — | 6,007 |
| Net loss for the three months ended March 31, 2026 | — | — | — | (69,707) | — | (69,707) |
| Other comprehensive loss | — | — | — | — | (282) | (282) |
| Balance at March 31, 2026 | 72,134,066 | $7 | $786,313 | $(532,618) | $322 | $254,024 |
| Share-based compensation under the Equity Incentive Plan | — | — | 2,546 | — | — | 2,546 |
| Options exercised under the Equity Incentive Plan | 45,000 | — | 551 | — | — | 551 |
| Issuance of Class A Ordinary Shares under the Sales Agreement, net of transaction costs | 2,427,619 | — | 44,312 | — | — | 44,312 |
| Issuance of Class A Ordinary Shares and Pre-Funded Warrants under the 2026 Offering, net of transaction costs | 9,000,000 | 1 | 189,758 | — | — | 189,759 |
| Stamp duty fees for capital injection from MoonLake to MoonLake AG | — | — | (1,500) | — | — | (1,500) |
| Net loss for the three months ended June 30, 2026 | — | — | — | (61,805) | — | (61,805) |
| Other comprehensive income | — | — | — | — | 308 | 308 |
| Balance at June 30, 2026 | 83,606,685 | $8 | $1,021,980 | $(594,423) | $630 | $428,195 |
| Share-based compensation under the Equity Incentive Plan | — | — | 2,849 | — | — | 2,849 |
| Issuance of Class A shares upon exercise of the Over-Allotment Option, net of transaction costs | 1,500,000 | — | 28,472 | — | — | 28,472 |
| Net loss for the three months ended September 30, 2026 | — | — | — | (79,545) | — | (79,545) |
| Other comprehensive income | — | — | — | — | 1,657 | 1,657 |
| Balance at September 30, 2026 | 85,106,685 | $8 | $1,053,301 | $(673,968) | $2,287 | $381,628 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.